HIGHLIGHTS
- who: Hewlett-Packard Company from the Nottingham University Innovation Park, Nottingham, United Kingdom have published the paper: Conference , in the Journal: (JOURNAL)
SUMMARY
Attention Deficit-Hyperactivity Disorder (ADHD) is characterised by developmentally inappropriate and impairing levels of inattention, hyperactivity and impulsivity. During the medication initiation and titration phase, NICE recommends that clinicians should maintain weekly contact with their patients, and monitor treatment response and adverse effects at each dose change. Because of constraints on time and resources, routine monitoring of response to treatment and changes in symptoms over time currently falls short of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.